



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Horner
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein

Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
Thomas M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gabby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Matthew E. Kelley
Michelle K. Holoubek
Marsha A. Rose

Christopher J. Walsh
W. Blake Coblenz
James J. Pohl
Young Tang
John T. Haran
Mark W. Rygiel

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse

Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

July 13, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8525
INTERNET ADDRESS:
BRIAND@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1636

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Appl. No. 10/551,054; § 371 Date: September 23, 2005
(U.S. National Phase of Intl. Appl. No. PCT/EP04/003164); I.A. Date: March 25, 2004)
For: **Melan-A-Carrier Conjugates**
Inventors: Martin F. BACHMANN *et al.*
Our Ref: 1700.0590000/BJD/WBC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08B (9 pages) citing eighty-three (83) documents;
3. Copies of eighty-three (83) cited documents: NPL1-NPL83;
4. Form PTO-1449 (9 pages) citing sixty-seven (67) documents;
5. Copies of forty-three (43) cited documents: AL1-AP1; AL2-AP2; AL3-AP3; AL4-AP4; AL5-AP5; AL6-AP6; AL3-AP3; AL4-AP4; AL5-AP5; AL6-AP6; AL7-AP7; AL8-AP8; and AL9-AN9; and
6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
July 13, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

BJD/WBC:cpn
Enclosures
556608_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Martin F. BACHMANN *et al.*

Appl. No.: 10/551,054
(U.S. National Phase of Intl. Appl. No.
PCT/EP04/003164)

Filed: September 23, 2005
(Int'l Filing Date: March 25, 2004)

For: **Melan-A-Carrier Conjugates**

Confirmation No.: 1432

Art Unit: 1636

Examiner: *To Be Assigned*

Atty. Docket: 1700.0590000/BJD/WBC

**Information Disclosure Statement
Filing Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO-1449 and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **AL1-AN9** and **NPL1-NPL83** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **AA1-AB3**, cited on the attached Form PTO-1449 are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents **AO1** and **AO3** cited on Form PTO-1449:

Document **AO1**, EP 0 201 416 B1, is in the French language. An English language abstract of document AO1 is attached as document **NPL83**.

Document **AO3**, WO 98/58751 A1, is in the French language. An English language abstract of document AO3 is located on the face page of said document.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: July 13, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

514634_1.DOC



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|-----|--------------------|------------|----------------------------|-------|-----------|---------------------------|
| | AA1 | 4,722,840 | 02/02/1988 | Valenzuela <i>et al.</i> | | | 09/19/1985 |
| | AB1 | 4,959,314 | 09/25/1990 | Mark <i>et al.</i> | | | 02/07/1985 |
| | AC1 | 5,143,726 | 09/01/1992 | Thornton <i>et al.</i> | | | 11/20/1989 |
| | AD1 | 5,565,548 | 10/15/1996 | Neurath <i>et al.</i> | | | 03/15/1993 |
| | AE1 | 5,698,424 | 12/16/1997 | Mastico <i>et al.</i> | | | § 371 Date: 01/03/1995 |
| | AF1 | 5,844,075 | 12/01/1998 | Kawakami and Rosenberg | | | 04/05/1995 |
| | AG1 | 5,874,560 | 02/23/1999 | Kawakami and Rosenberg | | | 04/22/1994 |
| | AH1 | 5,935,821 | 08/10/1999 | Chatterjee <i>et al.</i> | | | 11/21/1996 |
| | AI1 | 5,939,598 | 08/17/1999 | Kucherlapati <i>et al.</i> | | | 07/30/1992 |
| | AJ1 | 5,994,523 | 11/30/1999 | Kawakami and Rosenberg | | | 01/16/1998 |
| | AK1 | 6,025,470 | 02/15/2000 | Valmori <i>et al.</i> | | | 06/23/1997 |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL1 | EP 0 038 154 B1 | 10/21/1981 | Europe | | | Yes No |
| | AM1 | EP 0 385 610 B1 | 03/16/1994 | Europe | | | Yes No |
| | AN1 | EP 0 421 635 A1 | 04/10/1991 | Europe | | | Yes No |
| | AO1 | EP 0 201 416 B1 | 04/10/1991 | Europe | | | Yes No |
| | AP1 | WO 92/13081 A1 | 08/06/1992 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|----|--|--|
| AR | | |
| AS | | |
| AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | |
|--|--|--|
| FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> | ATTY. DOCKET NO. 1700.0590000/BJD/WBC | APPLICATION NO. 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | FIRST NAMED INVENTOR Bachmann, M. | |
| | PCT FILING DATE March 25, 2004 | ART UNIT <i>To Be Assigned</i> |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|-----|--------------------|------------|------------------------|-------|-----------|-------------|
| | AA2 | 6,231,864 B1 | 05/15/2001 | Birkett | | | 02/11/1999 |
| | AB2 | 6,270,778 B1 | 08/07/2001 | Kawakami and Rosenberg | | | 03/12/1999 |
| | AC2 | 6,277,956 B1 | 08/21/2001 | Valmori <i>et al.</i> | | | 04/16/1998 |
| | AD2 | 6,326,200 B1 | 12/04/2001 | Valmori <i>et al.</i> | | | 06/18/1998 |
| | AE2 | 6,368,857 B1 | 04/09/2002 | Valmori <i>et al.</i> | | | 10/05/1999 |
| | AF2 | 6,380,364 B1 | 04/30/2002 | Mueller <i>et al.</i> | | | 10/06/1999 |
| | AG2 | 6,384,190 B1 | 05/07/2002 | Valmori <i>et al.</i> | | | 12/14/1999 |
| | AH2 | 6,627,202 B2 | 09/30/2003 | Murray | | | 06/04/2001 |
| | AI2 | 2003/0050268 A1 | 03/13/2003 | Krieg and Berg | | | 03/29/2002 |
| | AJ2 | 6,537,560 B1 | 03/25/2003 | Kawakami and Rosenberg | | | 05/05/1998 |
| | AK2 | 2003/0082804 A1 | 05/01/2003 | Valmori <i>et al.</i> | | | 02/21/2001 |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL2 | EP 0 578 293 A1 | 01/12/1994 | Europe | | | Yes No |
| | AM2 | WO 94/14969 A1 | 07/07/1994 | WIPO | | | Yes No |
| | AN2 | WO 95/29193 A2 | 11/02/1995 | WIPO | | | Yes No |
| | AO2 | WO 96/30523 A2 | 10/03/1996 | WIPO | | | Yes No |
| | AP2 | WO 98/40100 A1 | 09/17/1998 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|--|--|
| | AR | | |
| | AS | | |
| | AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|-----|--------------------|------------|------------------------|-------|-----------|-------------|
| | AA3 | 6,719,978 B2 | 04/13/2004 | Schiller <i>et al.</i> | | | 04/13/2001 |
| | AB3 | 6,965,017 B2 | 11/15/2005 | Kawakami and Rosenberg | | | 07/03/2001 |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL3 | WO 98/49195 A1 | 11/05/1998 | WIPO | | | Yes No |
| | AM3 | WO 98/50071 A1 | 11/12/1998 | WIPO | | | Yes No |
| | AN3 | WO 98/58951 A1 | 12/30/1998 | WIPO | | | Yes No |
| | AO3 | WO 98/58751 A1 | 12/30/1998 | WIPO | | | Yes No |
| | AP3 | WO 99/28478 A1 | 06/10/1999 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|--|--|
| | AR | | |
| | AS | | |
| | AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|--------------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL4 | WO 99/40934 A1 | 08/19/1999 | WIPO | | | Yes No |
| | AM4 | WO 99/57289 A2 | 11/11/1999 | WIPO | | | Yes No |
| | AN4 | WO 00/23955 A1 | 04/27/2000 | WIPO | | | Yes No |
| | AO4 | WO 00/32227 A2 | 06/08/2000 | WIPO | | | Yes No |
| | AP4 | WO 00/37610 A2 | 06/29/2000 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|--|--|
| | AR | | |
| | AS | | |
| | AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (*National Phase of
Intl. Appl. No. PCT/EP04/003164*)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
*To Be Assigned***U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|--------------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL5 | WO 00/39304 A2 | 07/06/2000 | WIPO | | | Yes No |
| | AM5 | WO 00/50461 A1 | 08/31/2000 | WIPO | | | Yes No |
| | AN5 | WO 00/62800 A2 | 10/26/2000 | WIPO | | | Yes No |
| | AO5 | WO 01/16320 A1 | 03/08/2001 | WIPO | | | Yes No |
| | AP5 | WO 01/22972 A2 | 04/05/2001 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|--|--|
| | AR | | |
| | AS | | |
| | AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|--------------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL6 | WO 01/22990 A2 | 04/05/2001 | WIPO | | | Yes No |
| | AM6 | WO 01/56603 A1 | 08/09/2001 | WIPO | | | Yes No |
| | AN6 | WO 01/58478 A1 | 08/16/2001 | WIPO | | | Yes No |
| | AO6 | WO 01/77158 A1 | 10/18/2001 | WIPO | | | Yes No |
| | AP6 | WO 01/85208 A2 | 11/15/2001 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|--|--|
| | AR | | |
| | AS | | |
| | AT | | |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|--------------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL7 | WO 01/98333 A2 | 12/27/2001 | WIPO | | | Yes No |
| | AM7 | WO 02/14478 A2 | 02/21/2002 | WIPO | | | Yes No |
| | AN7 | WO 02/053141 A2 | 07/11/2002 | WIPO | | | Yes No |
| | AO7 | WO 02/056905 A2 | 07/25/2002 | WIPO | | | Yes No |
| | AP7 | WO 02/056907 A2 | 07/25/2002 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|--|--|
| | AR | | |
| | AS | | |
| | AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|--------------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL8 | WO 03/024480 A2 | 03/27/2003 | WIPO | | | Yes No |
| | AM8 | WO 03/024481 A2 | 03/27/2003 | WIPO | | | Yes No |
| | AN8 | WO 03/031466 A2 | 04/17/2003 | WIPO | | | Yes No |
| | AO8 | WO 03/039225 A2 | 05/15/2003 | WIPO | | | Yes No |
| | AP8 | WO 03/040164 A2 | 05/15/2003 | WIPO | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|--|--|
| | AR | | |
| | AS | | |
| | AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|--------------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|-----|--------------------|------------|---------|-------|-----------|-------------|
| | AL9 | WO 03/059386 A2 | 07/24/2003 | WIPO | | | Yes No |
| | AM9 | WO 04/000351 A1 | 12/31/2003 | WIPO | | | Yes No |
| | AN9 | WO 04/007538 A2 | 01/22/2004 | WIPO | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|--|--|
| | AR | | |
| | AS | | |
| | AT | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 1 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL1 | Adams, S.E., <i>et al.</i> , "The expression of hybrid HIV:Ty virus-like particles in yeast," <i>Nature</i> 329:68-70, Nature Publishing Group (1987) | |
| | NPL2 | Addo, M.M., <i>et al.</i> , "Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load," <i>J. Virol.</i> 77:2081-2092, American Society for Microbiology (February 2003) | |
| | NPL3 | Bachmann, M.F., and Zinkernagel, R., "The influence of virus structure on antibody responses and virus serotype formation," <i>Immunol. Today</i> 17:553-558, Elsevier Science (1996) | |
| | NPL4 | Bachmann, M.F., and Zinkernagel, R.M., "Neutralizing Antiviral B Cell Responses," <i>Ann. Rev. Immunol.</i> 15:235-270, Annual Reviews, Inc. (1997) | |
| | NPL5 | Brown, W.L., <i>et al.</i> , "RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation," <i>Interviol.</i> 45:371-380, S. Karger AG (July-December 2002) | |
| | NPL6 | Buonaguro, L., <i>et al.</i> , "High efficient production of Pr55 ^{gag} virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A," <i>Antiviral Res</i> 49:35-47, Elsevier Science B.V. (2001) | |
| | NPL7 | Chackerian, B., <i>et al.</i> , "Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles," <i>Proc. Natl. Acad. Sci. USA</i> 96:2373-2378, The National Academy of Sciences (1999) | |
| | NPL8 | Chen, J.L., <i>et al.</i> , "Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL," <i>J. Immunol.</i> 165:948-55, The American Association of Immunologists (2000) | |
| | NPL9 | Cohen, P.A., <i>et al.</i> , "CD4 ⁺ T-Cells from Mice Immunized to Syngeneic Sarcomas Recognize Distinct, Non-Shared Tumor Antigens," <i>Cancer Research</i> 54:1055-8, American Association for Cancer Research (1994) | |
| | NPL10 | De Clercq, E., "Interferon Induction by Polynucleotides, Modified Polynucleotides, and Polycarboxylates," <i>Methods Enzymol.</i> 78:227-36, Academic Press, Inc. (1981) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 2 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL11 | Dudley, M.E., <i>et al.</i> , "Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes," <i>Science</i> 298:850-854, American Association for the Advancement of Science (October 2002) | |
| | NPL12 | Engleman, E.G., "Dendritic cells: Potential role in cancer therapy," <i>Cytotechnol.</i> 25:1-8, Kluwer Academic Publishers (1997) | |
| | NPL13 | Fehr, T., <i>et al.</i> , "Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies," <i>J. Exp. Med.</i> 185:1785-92, The Rockefeller University Press (1997) | |
| | NPL14 | Fehr, T., <i>et al.</i> , "T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles," <i>Proc. Natl. Acad. Sci. USA</i> 95:9477-9481, The National Academy of Sciences (1998) | |
| | NPL15 | Firat, H., <i>et al.</i> , "H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," <i>Eur. J. Immunol.</i> 29:3112-3121, WILEY-VCH Verlag GmbH (1999) | |
| | NPL16 | Fitch, J., <i>et al.</i> , "Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response," <i>Vaccine</i> 13:1051-1057, Elsevier Science (1995) | |
| | NPL17 | Gerber, S., <i>et al.</i> , "Human Papillomavirus Virus-Like Particles Are Efficient Oral Immunogens when Coadministered with <i>Escherichia coli</i> Heat-Labile Enterotoxin Mutant R192G or CpG DNA," <i>J. Virol.</i> 75:4752-60, American Society for Microbiology (2001) | |
| | NPL18 | Geysen, H.M., <i>et al.</i> , "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Natl. Acad. Sci. USA</i> 81:3998-4002, The National Academy of Sciences (1984) | |
| | NPL19 | Gilbert, S.C., <i>et al.</i> , "A protein particle vaccine containing multiple malaria epitopes," <i>Nat. Biotechnol.</i> 15:1280-1284, Nature America Publishing (1997) | |
| | NPL20 | Gluckman, J.C., <i>et al.</i> , "In vitro generation of human dendritic cells and cell therapy," <i>Cytokines Cell. Mol. Ther.</i> 3:187-96, Martin Dunitz Ltd. (1997) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/551,054 (National Phase of Intl. Appl. No. PCT/EP04/003164) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 3 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL21 | Golmohammadi, R., et al., "The crystal structure of bacteriophage Q β at 3.5 Å resolution," <i>Structure</i> 4:543-554, Current Biology Ltd. (1996) | |
| | NPL22 | Graff-Dubois, S., et al., "Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy," <i>J. Immunol.</i> 169:575-580, The American Association of Immunologists, Inc. (July 2002) | |
| | NPL23 | Harada, M., et al., "Use of an <i>in Vitro</i> Immunoselected Tumor Line to Identify Shared Melanoma Antigens Recognized by HLA-A*0201-restricted T Cells," <i>Cancer Res.</i> 61:1089-1094, American Association for Cancer Research (2001) | |
| | NPL24 | Huston, J.S., et al., "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," <i>Methods Enzymol.</i> 203:46-88, Academic Press, Inc. (1991) | |
| | NPL25 | Jegerlehner, A., et al., "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," <i>Vaccine</i> 20:3104-3012, Elsevier Science Ltd. (August 2002) | |
| | NPL26 | Kaisho, T. and Akira, S., "Toll-like receptors as adjuvant receptors," <i>Biochim. Biophys. Acta</i> 1589:1-13, Elsevier Science (February 2002) | |
| | NPL27 | Kang, C.Y., et al., "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles," <i>Biol. Chem.</i> 380:353-64, Walter De Gruyter (1999) | |
| | NPL28 | Klinman, D.M., et al., "Immunotherapeutic Applications of CpG-Containing Oligodeoxynucleotides," <i>Drug News Perspect.</i> 13:289-296, Prous Science (2000) | |
| | NPL29 | Klovins, J., et al., "Nucleotide sequence of a ssRNA phage from <i>Acinetobacter</i> : kinship to coliphages," <i>J. Gen. Virol.</i> 83:1523-1533, SGM (June 2002) | |
| | NPL30 | Kobayashi H., et al., "Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient," <i>Immunogenet.</i> 47:398-403, Springer-Verlag (1998) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 4 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL31 | Kobayashi, H., <i>et al.</i> , "Tumor-reactive T Helper Lymphocytes Recognize a Promiscuous MAGE-A3 Epitope Presented by Various Major Histocompatibility Complex Class II Alleles," <i>Cancer Res.</i> 61:4773-4778, American Association for Cancer Research (2001) | |
| | NPL32 | Kozlovskaya, T. M., <i>et al.</i> , "RNA Phage Q β Coat Protein as a Carrier for Foreign Epitopes," <i>Interviol.</i> 39:9-15, S. Karger AG Basel (1996) | |
| | NPL33 | Kozlovskaya, T.M., <i>et al.</i> , "Recombinant RNA phage Q β capsid particles synthesized and self-assembled in <i>Escherichia coli</i> ," <i>Gene</i> 137:133-137, Elsevier Science Publishers B.V. (1993) | |
| | NPL34 | Kratz, P.A., <i>et al.</i> , "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," <i>Proc. Natl. Acad. Sci. USA</i> 96:1915-1920, The National Academy of Sciences (1999) | |
| | NPL35 | Krug, A., <i>et al.</i> , "Identification of CpG oligonucleotide sequences with high induction of IFN- α/β in plasmacytoid dendritic cells," <i>Eur. J. Immunol.</i> 31:2154-63, WILEY Verlag GmbH (2001) | |
| | NPL36 | Kuramoto, E., <i>et al.</i> , "Oligonucleotide Sequences Required for Natural Killer Cell Activation," <i>Jpn. J. Cancer Res.</i> 83:1128-1131, Japanese Cancer Association (1992) | |
| | NPL37 | Lechner, F., <i>et al.</i> , "Virus-like Particles as a Modular System for Novel Vaccines," <i>Interviol.</i> 45:212-217, S. Karger AG (July-December 2002) | |
| | NPL38 | Levy, H.B., "Induction of Interferon <i>in Vivo</i> and <i>in Vitro</i> by Polynucleotides and Derivatives, and Preparation of Derivatives," <i>Methods Enzymol.</i> 78:242-51, Academic Press, Inc. (1981) | |
| | NPL39 | Li, Y., <i>et al.</i> , "Vaccination Against Angiogenesis-Associated Antigens: A Novel Cancer Immunotherapy Strategy," <i>Curr. Mol. Med.</i> 3:773-779, Bentham Science Publishers Ltd. (December 2003) | |
| | NPL40 | Linette, G.P., <i>et al.</i> , "In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8 ⁺ T cells in Patients with Melanoma," <i>J. Immunol.</i> 164:3402-3412, The American Association of Immunologists (2000) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 5 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL41 | Luo, L., <i>et al.</i> , "Induction of V3-Specific Cytotoxic T Lymphocyte Responses by HIV gag Particles Carrying Multiple Immunodominant V3 Epitopes of gp120," <i>Virol.</i> 240:316-325, Academic Press (1998) | |
| | NPL42 | Malling, H.-J., and Taudorf, E., "Allergenicity of alum-precipitated grass pollen extracts with different RAST activity," <i>Clin. Allergy</i> 17:399-404, Blackwell Scientific Publications (1987) | |
| | NPL43 | Martin, S.J., <i>et al.</i> , "Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses," <i>AIDS</i> 7:1315-23, Current Science Ltd. (1993) | |
| | NPL44 | Moss, R.B., <i>et al.</i> , "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides," <i>Vaccine</i> 18:1081-7, Elsevier Science Ltd. (2000) | |
| | NPL45 | Neirynck, S., <i>et al.</i> , "A universal influenza A vaccine based on the extracellular domain of the M2 protein," <i>Nature Med.</i> 5:1157-63, Nature Publishing Company (1999) | |
| | NPL46 | Nieland, J.D., <i>et al.</i> , "Chimeric Papillomavirus Virus-like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response," <i>J. Cell. Biochem.</i> 73:145-152, Wiley-Liss, Inc. (1999) | |
| | NPL47 | Nielsen, M.B., <i>et al.</i> , "Status of Activation of Circulating Vaccine-Elicited CD8 ⁺ T Cells," <i>J. Immunol.</i> 165:2287-96, The American Association of Immunologists (2000) | |
| | NPL48 | Notka, F., <i>et al.</i> , "Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies," <i>Vaccine</i> 18:291-301, Elsevier Science Ltd. (2000) | |
| | NPL49 | Nussbaum, A.K., <i>et al.</i> , "PAPROC: a prediction algorithm for proteasomal cleavages available on the WWW," <i>Immunogenet.</i> 53:87-94, Springer-Verlag (2001) | |
| | NPL50 | Oxenius, A., <i>et al.</i> , "CpG-Containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines," <i>J. Virol.</i> 73:4120-4126, American Society for Microbiology (1999) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 6 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL51 | Panelli, M.C., <i>et al.</i> , "Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases," <i>J. Immunol.</i> 164:495-504, The American Association of Immunologists (2000) | |
| | NPL52 | Parkhurst, M.R., <i>et al.</i> , "Identification of a Shared HLA-A*0201-restricted T-Cell Epitope from the Melanoma Antigen Tyrosinase-related Protein 2 (TRP2)," <i>Cancer Res.</i> 58:4895-4901, American Association for Cancer Research (1998) | |
| | NPL53 | Pasek, M., <i>et al.</i> , "Hepatitis B virus genes and their expression in <i>E. coli</i> ," <i>Nature</i> 282:575-579, Macmillan Journals Ltd. (1979) | |
| | NPL54 | Pass, H.A., <i>et al.</i> , "Immunization of Patients with Melanoma Peptide Vaccines: Immunologic Assessment Using the ELISPOT Assay," <i>Cancer J. Sci. Am.</i> 4:316-323, Scientific American, Inc. (1998) | |
| | NPL55 | Pumpens, P. and Grens, E., "HBV Core Particles as a Carrier for B Cell/T Cell Epitopes," <i>Intervirology</i> 44:98-114, S. Karger AG (2001) | |
| | NPL56 | Pushko, P., <i>et al.</i> , "Analysis of RNA phage <i>fr</i> coat protein assembly by insertion, deletion and substitution mutagenesis," <i>Protein Eng.</i> 6::883-891, Oxford University Press (1993) | |
| | NPL57 | Rammensee, H., <i>et al.</i> , "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenet.</i> 50:213-219, Springer-Verlag (1999) | |
| | NPL58 | Roth, J.F., "The yeast Ty virus-like particles," <i>Yeast</i> 16:785-795, John Wiley & Sons, Ltd. (2000) | |
| | NPL59 | Rueda, P., <i>et al.</i> , "Minor Displacements in the Insertion Site Provoke Major Differences in the Induction of Antibody Responses by Chimeric Parvovirus-like Particles," <i>Virology</i> 263:89-99, Academic Press (1999) | |
| | NPL60 | Sallusto, F. and Lanzavecchia, A., "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α ," <i>J. Exp. Med.</i> 179:1109-1118, The Rockefeller University Press (1994) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 7 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL61 | Salunke, D.M., <i>et al.</i> , "Self-Assembly of Purified Polyomavirus Capsid Protein VP ₁ ," <i>Cell</i> 46:895-904, Cell Press (1986) | |
| | NPL62 | Sasnauskas, K., <i>et al.</i> , "Yeast Cells Allow High-Level Expression and Formation of Polyomavirus-Like Particles," <i>Biol. Chem.</i> 380:381-6, Walter de Gruyter (1999) | |
| | NPL63 | Skipper, J.C.A., <i>et al.</i> , "Mass-Spectrometric Evaluation of HLA-A*0201-Associated Peptides Identifies Dominant Naturally Processed Forms of CTL Epitopes from MART-1 and gp100," <i>Int. J. Cancer</i> 82:669-677, Wiley-Liss Inc. (1999) | |
| | NPL64 | Slepishkin, V.A., <i>et al.</i> , "Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein," <i>Vaccine</i> 13:1399-1402, Elsevier Science (1995) | |
| | NPL65 | Smiley, B.K. and Minion, F.C., "Enhanced readthrough of opal (UGA) stop codons and production of <i>Mycoplasma pneumoniae</i> P1 epitopes in <i>Escherichia coli</i> ," <i>Gene</i> 134:33-40, Elsevier Science Publishers B.V. (1993) | |
| | NPL66 | Sparwasser, T., <i>et al.</i> , "Immunostimulatory CpG-Oligodeoxynucleotides Cause Extramedullary Murine Hemopoiesis," <i>J. Immunol.</i> 162:2368-2374, The American Association of Immunologists (1999) | |
| | NPL67 | Speiser, D.E., <i>et al.</i> , "In vivo activation of melanoma-specific CD8 ⁺ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells," <i>Eur. J. Immunol.</i> 32:731-741, WILEY-VCH Verlag GmbH (March 2002) | |
| | NPL68 | Steinman, R.M., "Dendritic cells and immune-based therapies," <i>Exp. Hematol.</i> 24:859-862, Elsevier Science Inc. (1996) | |
| | NPL69 | Storni, T., <i>et al.</i> , "Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles," <i>J. Immunol.</i> 168:2880-2886, The American Association of Immunologists (March 2002) | |
| | NPL70 | Sun, Y., <i>et al.</i> , "Identification of a New HLA-A*0201-Restricted T-Cell Epitope from the Tyrosinase-Related Protein 2 (TRP2) Melanoma Antigen," <i>Int. J. Cancer</i> 87:399-404, Wiley-Liss Inc. (2000) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 8 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL71 | Taylor, K.M., <i>et al.</i> , "Position-Dependent Processing of Peptides Presented on the Surface of Cowpea Mosaic Virus," <i>Biol. Chem.</i> 380:387-392, Walter de Gruyter (1999) | |
| | NPL72 | Toes, R.E., <i>et al.</i> , "Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products," <i>J. Exp. Med.</i> 194:1-12, The Rockefeller University Press (2001) | |
| | NPL73 | Torrence, P.F., "Preparation of a Synthetic Polynucleotide Interferon Inducer," <i>Meth. Enzymol.</i> 78:326-331, Academic Press, Inc. (1981) | |
| | NPL74 | Touzé, A., <i>et al.</i> , "Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells," <i>J. Gen. Virol.</i> 82:3005-3009, Society for General Microbiology (2001) | |
| | NPL75 | Valmori, D., <i>et al.</i> , "Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues," <i>J. Immunol.</i> 160:1750-1758, The American Association of Immunologists (1998) | |
| | NPL76 | Valmori, D., <i>et al.</i> , "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," <i>J. Immunol.</i> 161:6956-6962, The American Association of Immunologists (1998) | |
| | NPL77 | van Schooten, W.C.A., <i>et al.</i> , "Biological properties of dendritic cells: implications to their use in the treatment of cancer," <i>Mol. Med. Today</i> 255:254-260, Elsevier Science (1997) | |
| | NPL78 | Vasiljeva, I., <i>et al.</i> , "Mosaic Q β coats as a new presentation model," <i>FEBS Lett</i> 431:7-11, Elsevier Science B.V. (1998) | |
| | NPL79 | Witte, L., <i>et al.</i> , "Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy," <i>Cancer Metastasis Rev.</i> 17:155-161, Kluwer Academic Publishers (1998) | |
| | NPL80 | Yuan, T.T., <i>et al.</i> , "Subtype-Independent Immature Secretion and Subtype-Dependent Replication Deficiency of a Highly Frequent, Naturally Occurring Mutation of Human Hepatitis B Virus Core Antigen," <i>J. Virol.</i> 73:10122-10128, American Society for Microbiology (1999) | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/551,054 (<i>National Phase of Intl. Appl. No. PCT/EP04/003164</i>) |
| | | | | PCT Filing Date | March 25, 2004 |
| | | | | First Named Inventor | Martin F. BACHMANN |
| | | | | Art Unit | To Be Assigned |
| | | | | Examiner Name | To Be Assigned |
| Sheet | 9 | of | 9 | Attorney Docket Number | 1700.0590000/BJD/WBC |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL81 | Zarour, H.M., et al., "NY-ESO-1 119-143 Is a Promiscuous Major Histocompatibility Complex Class II T-Helper Epitope Recognized by Th1- and Th2-Type Tumor-reactive CD4 ⁺ T Cells," <i>Cancer Res.</i> 62:213-218, American Association for Cancer Research (January 2002) | |
| | NPL82 | Zhou, S. and Standing, D.N., "Cys Residues of the Hepatitis B Virus Capsid Protein Are Not Essential for the Assembly of Viral Core Particles but Can Influence Their Stability," <i>J. Virol.</i> 66:5393-5398, American Society for Microbiology (1992) | |
| | NPL83 | Dialog File 351, Accession No. 4796523, Derwent WPI English language abstract for EP 0 201 416 A1, cited as document AO1 on Form PTO-1449 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

514074_1.DOC

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.